Daily Sepsis Research Analysis
Analyzed 15 papers and selected 3 impactful papers.
Summary
Three impactful sepsis studies span translational immunology, implementation science, and time-critical surgical care. A postbiotic from Akkermansia muciniphila protected against sepsis by reprogramming immunity via the IDO1–kynurenine–AhR axis; a UK multi-hospital analysis found no overall increase in late diagnoses after adopting the Kaiser sepsis risk calculator; and a national U.S. study showed that decompression within 24 hours for septic obstructing ureteral stones reduced in-hospital mortality.
Research Themes
- Microbiome-derived postbiotics and immune-metabolic reprogramming in sepsis
- Implementation of neonatal sepsis risk stratification tools at scale
- Time-to-source-control in obstructive urosepsis
Selected Articles
1. Akkermansia muciniphila-derived postbiotics reprogram immune balance to combat sepsis via the IDO1/Kyn/AhR metabolic axis.
In mouse LPS/CLP and a porcine sepsis model, hypoacylated lipooligosaccharides from Akkermansia muciniphila protected against sepsis by inducing semi-mature dendritic cells with IDO1 upregulation, increasing kynurenine and AhR signaling to drive Treg differentiation and suppress Th17 responses. Effects were abrogated by an IDO1 inhibitor and mimicked by kynurenine, and safety was demonstrated in mice.
Impact: This mechanistic, cross-species work identifies a tractable immune–metabolic axis (IDO1/Kyn/AhR) targeted by a defined postbiotic, offering a novel therapeutic concept for sepsis.
Clinical Implications: While preclinical, findings support advancing microbiome-derived postbiotics and IDO1–kynurenine–AhR modulators as candidate adjuvants for sepsis, with biomarker-guided designs.
Key Findings
- ALOS protected against sepsis in LPS and CLP mouse models and in a porcine model, reducing systemic inflammation and organ injury.
- Mechanism: ALOS induced semi-mature dendritic cells with increased IDO1, elevating kynurenine to activate AhR and promote Treg differentiation while reducing Th17 cells.
- Reversal and mimicry: The IDO1 inhibitor NLG919 abolished protection, whereas exogenous kynurenine reproduced benefits; short-term safety of ALOS was shown in mice.
Methodological Strengths
- Cross-species validation in both rodent and porcine sepsis models
- Mechanistic dissection with inhibitor rescue and metabolite mimicry, supported by dendritic cell phenotyping and transcriptomics
Limitations
- Preclinical models may not fully recapitulate human sepsis heterogeneity and timing of intervention
- Dosing schedule and route (i.p.) may not translate directly to clinical practice
Future Directions: Phase 1 safety/pharmacokinetic studies of ALOS or analogs, followed by biomarker-enriched early-phase trials targeting the IDO1–Kyn–AhR axis in sepsis; exploration of combinatorial strategies with antibiotics and source control.
INTRODUCTION: Sepsis is a life-threatening syndrome of organ dysfunction driven by a dysregulated immune response. Effective therapeutic strategies to restore immune homeostasis remain limited. Hypoacylated lipooligosaccharides (ALOS) from Akkermansia muciniphila have emerged as potential immunomodulatory postbiotics, yet their therapeutic potential in sepsis and the underlying mechanisms remain unexplored. OBJECTIVES: This study aims to investigate whether ALOS confers protection in experimental models of sepsis induced by toxic lipopolysaccharides (LPS) or cecal ligation and puncture (CLP), and the mechanism by which ALOS exerts its anti-inflammatory and regulatory effects. METHODS: In LPS or CLP-induced mouse sepsis models and a porcine sepsis model, ALOS (0.2 mg/kg, i.p.) was administered once every two days before challenge or half an hour post-surgery. Survival rates, physiological and biochemical parameters were assessed. Based on 16S rRNA gene amplicon sequencing and barrier function assessment, the changes of the colonic microbiota and metabolites and anti-inflammatory capacity were analyzed. The anti-inflammatory and immunomodulatory mechanisms of ALOS were investigated through dendritic cell phenotyping, transcriptomic analysis, inhibitor assays, and conditioned medium experiments. Finally, the safety of ALOS was evaluated in C57BL/6J mice following one-week administration (0.2 mg/kg, i.p.). RESULTS: ALOS pretreatment significantly suppresses sepsis, reduces the proportion of pro-inflammatory Th17 cells, and increases regulatory T cells (Treg). Mechanistically, ALOS induced semi‑mature dendritic cells with upregulated IDO1 expression, leading to enhanced production of kynurenine (Kyn). Kyn activated the aryl hydrocarbon receptor (AhR) to drive Treg differentiation. The protective effect of ALOS was completely reversed by NLG919, whereas Kyn administration mimicked the therapeutic benefit. ALOS also produced therapeutic protection on sepsis. In a porcine sepsis model, pretreatment of ALOS exerted systemic anti‑inflammatory effects and protected multiple organs. CONCLUSION: This study highlights the protective role of ALOS in sepsis and identifies the IDO1-Kyn-AhR immune axis as the major underlying mechanism.
2. Impact of Kaiser permanente early-onset sepsis risk calculator implementation in hospitals, England: pre-post intervention cohort analysis.
Across 222,122 births in 16 NHS Trusts, adopting the KP-SRC did not increase late EOS diagnoses overall, with similar proportions diagnosed on readmission pre- versus post-implementation (9.6% vs 10.8%). Mortality did not differ, though the study was not powered for this outcome; hospital-level variation supports the need for local monitoring.
Impact: Provides large-scale, real-world safety data supporting KP-SRC implementation without increasing late EOS diagnoses, addressing a key concern for policy and practice.
Clinical Implications: Supports adopting KP-SRC with robust local audit of readmissions and outcomes to ensure safety; reinforces implementation frameworks and surveillance after practice change.
Key Findings
- No overall increase in late EOS diagnoses after KP-SRC implementation across 16 NHS Trusts (readmission diagnosis 9.6% pre vs 10.8% post; p=0.67).
- Mortality among microbiologically confirmed and clinically diagnosed EOS cases did not differ pre vs post, though the study was underpowered for mortality.
- Heterogeneity across hospitals suggests the need for site-level monitoring despite overall safety.
Methodological Strengths
- Large, population-scale linked datasets spanning multiple hospitals and years
- Pre–post design with clearly defined microbiological and clinical EOS outcomes
Limitations
- Quasi-experimental design susceptible to secular trends and unmeasured confounding
- Underpowered for mortality and potential misclassification from administrative codes
Future Directions: Prospective implementation studies with standardized auditing, antibiotic utilization metrics, and safety endpoints; equity-focused analyses to address inter-hospital variability.
OBJECTIVE: To investigate the impact of transition from National Institute for Health and Care Excellence (NICE) guidelines to Kaiser Permanente Neonatal Sepsis Risk Calculator (KP-SRC) on early-onset sepsis (EOS) diagnosis and mortality. STUDY DESIGN: Pre-post intervention analysis across 16 NHS hospital Trusts in England (2015-2023) 18 months before and after NICE to KP-SRC transition. Liveborn infants of any gestational age (N=222 122) were extracted from Hospital Episode Statistics and linked to national microbiological data and birth and death registrations. MAIN OUTCOMES: Cases were identified within first 3 days of life during birth admission or first 7 days if readmitted and defined microbiologically (positive microbiology from normally sterile site) or clinically (International Classification of Diseases, 10th Revision codes). Deaths occurring within the neonatal period attributable to EOS and proportion of EOS cases diagnosed during readmission were identified. RESULTS: There was no evidence of an increase in late diagnosis of EOS after KP-SRC implementation across hospitals combined, with the proportion of microbiologically confirmed cases diagnosed on readmission similar to pre-implementation (9.6% vs 10.8%; p=0.67). Variation between hospitals was observed, with non-significant increases in readmission diagnosis (vs diagnosis in birth episode) post implementation in 9 of 15. There was no difference in mortality for microbiologically confirmed cases or deaths based on clinical diagnosis though the study was not powered for these outcomes. CONCLUSION: No overall increase in late diagnoses due to EOS was observed after switching to KP-SRC but variation between hospitals, including non-significant increases in readmission diagnoses in some, injects caution and underscores the importance of local monitoring post implementation.
3. Early urinary decompression and mortality in septic obstructing ureteral stones: a nationwide comparative-effectiveness study.
In a national cohort of 9,172 adults with sepsis and obstructing ureteral stones, urinary decompression was associated with lower in-hospital mortality versus conservative care, and decompression within 24 hours halved adjusted odds of death compared with later intervention. Differences between stenting and PCN were exploratory and likely confounded by indication.
Impact: Quantifies the time-critical benefit of decompression and supports prioritizing ≤24-hour source control in obstructive urosepsis using multiple causal-inference methods.
Clinical Implications: Hospitals should hardwire pathways to achieve decompression within 24 hours for septic obstructing stones, leveraging rapid imaging, early urology involvement, and escalation to PCN when stenting is unfeasible.
Key Findings
- Decompression vs conservative care: in-hospital mortality 1.6% vs 4.0% (risk difference −2.4%, 95% CI −3.2 to −1.7; NNT ≈ 41).
- Timing effect: late (>24 h) vs early (≤24 h) decompression associated with higher mortality (OR 2.17, 95% CI 1.38–3.41) and more AKI, ventilation, and dialysis.
- Modality comparison (exploratory): PCN showed higher adjusted mortality than stenting (5.5% vs 2.8%; OR 2.05, 95% CI 1.31–3.09), likely reflecting confounding by indication.
Methodological Strengths
- Large national sample with multiple complementary causal-inference approaches (PSM, overlap weighting, IV, time-dependent models)
- Pre-specified adjustment set and robust sensitivity analyses
Limitations
- Observational design with potential residual confounding and coding misclassification
- Modality comparisons (stent vs PCN) are susceptible to confounding by feasibility and patient selection
Future Directions: Prospective time-to-intervention quality initiatives and, where feasible, randomized or quasi-experimental studies to optimize workflows; pragmatic trials or registries to clarify modality selection.
BACKGROUND: Septic obstructing ureteral stones are a time-critical urological emergency. Although urgent drainage is recommended, uncertainty persists regarding the comparative effectiveness of decompression strategies and the influence of timing in real-world practice. METHODS: We analyzed adults with sepsis or septic shock and obstructing ureteral stones (n = 9,172) from the U.S. HCUP National Inpatient Sample (2016-2022). Exposures included any decompression (ureteral stent or percutaneous nephrostomy [PCN]) versus conservative care, and decompression timing (same-day [day 0] vs. ≥ day 1; ≤ 24 h vs. > 24 h). The primary outcome was in-hospital mortality; secondary outcomes were acute kidney injury (AKI), mechanical ventilation, dialysis, and length of stay. Adjusted associations were estimated using propensity score matching, overlap weighting, instrumental variable (IV) analysis, and landmark/time-dependent survival models with a prespecified 12-variable adjustment set. RESULTS: Overall mortality was 2.5%. Decompression was associated with lower mortality than conservative care (1.6% vs. 4.0%; risk difference - 2.4% [95% CI - 3.2 to - 1.7]; number needed to treat ≈ 41). Late decompression (> 24 h) versus early (≤ 24 h) was associated with higher odds of mortality (OR 2.17 [1.38-3.41]), AKI, ventilation, and dialysis. In exploratory analyses among decompressed patients, PCN showed higher adjusted mortality than stenting (5.5% vs. 2.8%; OR 2.05 [1.31-3.09]); IV results were directionally consistent but likely reflect residual confounding by indication and feasibility. CONCLUSION: Urgent decompression, particularly within 24 h, was associated with lower in-hospital mortality and fewer organ-failure outcomes. Modality differences should be interpreted as hypothesis-generating; PCN remains essential when retrograde stenting is not feasible.